IL1B and gout: Some of them are under investigation for inflammatory diseases such as Inzomelid for CAPS (phase I) (ClinicalTrials.gov Identifier: NCT04015076), OLT1177 for treatment of gout flares (phase II) (44), and ZYIL1 for viral inflammatory diseases characterised by cytokine IL-1β flare.